Virtual Library
Start Your Search
J. Liu
Author of
-
+
Best abstracts selected from submissions 5 (ID 6)
- Event: ACLC 2018
- Type: Oral Session
- Track:
- Presentations: 1
- Moderators:
- Coordinates: 11/09/2018, 16:20 - 17:00, Crystal Ballroom 1
-
+
OA09 - Preliminary Clinical Activity of Repotrectinib (TPX-0005) in Advanced ROS1 Fusion-Positive Non-Small Cell Lung Cancer (ID 178)
16:20 - 17:00 | Author(s): J. Liu
- Abstract
Background:
Patients (pts) with ROS1+ advanced NSCLC can be effectively treated with ROS1 tyrosine kinase inhibitors (TKIs). However, acquired resistance inevitably develops, resulting in disease relapse. Repotrectinib is a potent next-generation ROS1/TRK/ALK TKI, which inhibits ROS1 with a >90-fold greater potency (IC50 <0.2 nM) than crizotinib. Preclinical studies demonstrate robust activity of repotrectinib against all known clinical ROS1 resistance mutations, including ROS1 G2032R resistance solvent-front mutation.
Method:
In this phase I study (NCT03093116), eligible adult pts with TKI-na